Back to User profile » Prof. Dr. Hugo A Katus

Papers published by Prof. Dr. Hugo A Katus:


Trigger-Specific Remodeling of KCa2 Potassium Channels in Models of Atrial Fibrillation

Rahm AK, Gramlich D, Wieder T, Müller ME, Schoeffel A, El Tahry FA, Most P, Heimberger T, Sandke S, Weis T, Ullrich ND, Korff T, Lugenbiel P, Katus HA, Thomas D

Pharmacogenomics and Personalized Medicine 2021, 14:579-590

Published Date: 20 May 2021

COPD in patients after heart transplantation is associated with a prolonged hospital stay, early posttransplant atrial fibrillation, and impaired posttransplant survival

Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Darche FF, Thomas D, Bruckner T, Katus HA, Ehlermann P, Doesch AO

Clinical Epidemiology 2018, 10:1359-1369

Published Date: 27 September 2018

Short vs prolonged dual antiplatelet treatment upon endovascular stenting of peripheral arteries

Kronlage M, Wassmann M, Vogel B, Müller OJ, Blessing E, Katus H, Erbel C

Drug Design, Development and Therapy 2017, 11:2937-2945

Published Date: 6 October 2017

Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation

Rivinius R, Helmschrott M, Ruhparwar A, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2017, 11:1827-1837

Published Date: 19 June 2017

Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy

Helmschrott M, Rivinius R, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2017, 11:1673-1680

Published Date: 7 June 2017

A comparative study on endovascular treatment of (sub)acute critical limb ischemia: mechanical thrombectomy vs thrombolysis

Kronlage M, Printz I, Vogel B, Blessing E, Müller OJ, Katus HA, Erbel C

Drug Design, Development and Therapy 2017, 11:1233-1241

Published Date: 18 April 2017

The influence of surgical technique on early posttransplant atrial fibrillation — comparison of biatrial, bicaval, and total orthotopic heart transplantation

Rivinius R, Helmschrott M, Ruhparwar A, Erbel C, Gleissner CA, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO

Therapeutics and Clinical Risk Management 2017, 13:287-297

Published Date: 8 March 2017

Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis

Preusch MR, Rusnak J, Staudacher K, Mogler C, Uhlmann L, Sievers P, Bea F, Katus HA, Blessing E, Staudacher I

Drug Design, Development and Therapy 2016, 10:2691-2699

Published Date: 26 August 2016

Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation

Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Schweizer PA, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2016, 10:677-686

Published Date: 16 February 2016

Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study

aus dem Siepen F, Bauer R, Aurich M, Buss SJ, Steen H, Altland K, Katus HA, Kristen AV

Drug Design, Development and Therapy 2015, 9:6319-6325

Published Date: 4 December 2015

Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis

Sievers P, Uhlmann L, Korkmaz-Icöz S, Fastner C, Bea F, Blessing E, Katus HA, Preusch MR

Drug Design, Development and Therapy 2015, 9:3935-3942

Published Date: 29 July 2015

Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation

Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2015, 9:1217-1224

Published Date: 24 February 2015

Anesthetic drug midazolam inhibits cardiac human ether-à-go-go-related gene channels: mode of action

Vonderlin N, Fischer F, Zitron E, Seyler C, Scherer D, Thomas D, Katus HA, Scholz EP,

Drug Design, Development and Therapy 2015, 9:867-877

Published Date: 16 February 2015

Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy

Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Klein B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2015, 9:93-102

Published Date: 17 December 2014

CCL19 and CCL21 modulate the inflammatory milieu in atherosclerotic lesions

Akhavanpoor M, Gleissner CA, Gorbatsch S, Doesch AO, Akhavanpoor H, Wangler S, Jahn F, Lasitschka F, Katus HA, Erbel C

Drug Design, Development and Therapy 2014, 8:2359-2371

Published Date: 27 November 2014

Inhibition of cardiac Kv1.5 potassium current by the anesthetic midazolam: mode of action

Vonderlin N, Fischer F, Zitron E, Seyler C, Scherer D, Thomas D, Katus HA, Scholz EP

Drug Design, Development and Therapy 2014, 8:2263-2271

Published Date: 7 November 2014

Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen

Helmschrott M, Beckendorf J, Akyol C, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2014, 8:1307-1314

Published Date: 9 September 2014

Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions

Doesch AO, Zhao L, Gleissner CA, Akhavanpoor M, Rohde D, Okuyucu D, Hakimi M, Dengler TJ, Katus HA, Erbel C

Drug Design, Development and Therapy 2014, 8:447-457

Published Date: 12 May 2014

Conversion to generic cyclosporine A in stable chronic patients after heart transplantation

Kraeuter M, Helmschrott M, Erbel C, Gleissner CA, Frankenstein L, Schmack B, Ruhparwar A, Ehlermann P, Katus HA, Doesch AO

Drug Design, Development and Therapy 2013, 7:1421-1426

Published Date: 28 November 2013

Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study

Doesch AO, Mueller S, Erbel C, Gleissner CA, Frankenstein L, Hardt S, Ruhparwar A, Ehlermann P, Dengler T, Katus HA

Drug Design, Development and Therapy 2013, 7:1323-1328

Published Date: 5 November 2013

Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation

Doesch AO, Mueller S, Akyol C, Erbel C, Frankenstein L, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA

Drug Design, Development and Therapy 2013, 7:1253-1258

Published Date: 21 October 2013

Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation

Gueler I, Mueller S, Helmschrott M, Oeing CU, Erbel C, Frankenstein L, Gleissner C, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA, Doesch AO

Drug Design, Development and Therapy 2013, 7:297-303

Published Date: 8 April 2013

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients

Doesch AO, Repp J, Hofmann N, Erbel C, Frankenstein L, Gleissner CA, Schmidt C, Ruhparwar A, Zugck C, Schnitzler P, Ehlermann P, Dengler TJ, Katus HA

Drug Design, Development and Therapy 2012, 6:289-295

Published Date: 12 October 2012

The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation

Schmidt C, Kisselbach J, Schweizer PA, Katus HA, Thomas D

Vascular Health and Risk Management 2011, 7:193-202

Published Date: 31 March 2011